[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Bovax Biotechnology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,81,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100574206","phase-2-to-evaluate-the-safety-and-immunogenicity-of-15-valent-hpv-recombinant-vaccine-in-chinese-people-aged-9-45-years-100574206",false,"NCT06756269","To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years","Inclusion Criteria:\n\n1. Participants aged 9-45；\n2. Participants aged 18-45 who can provide legal identification，participants aged 9-17 and their guardian can provide legal identification；\n3. Participants and\u002For their guardian sign an informed consent form;\n4. Axillary temperature less than 37.3 ℃（\\>14 years old）or less than 37.5℃（≤14 years old）at the time of enrollment；\n5. Be able to comply with study protocol requirements；\n6. Women with reproductive age take effective contraceptive measures within 2 weeks before enrollment in the study, and were not pregnant at the time of enrollment (negative blood pregnancy test), did not have lactation period, and had no birth plan within the 30 days after receiving the whole vaccination;\n7. Agree to take effective contraceptive measures within 30 days after receiving the whole vaccination (effective contraceptives include: oral contraceptives, injection or embedding contraceptives, sustained release topical contraceptives, hormone patches, intrauterine devices), sterilization, abstinence, condoms (male), diaphragms, cervical caps, etc.\n\nExclusion Criteria:\n\n1. Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV vaccines during the study period；\n2. Plan to participate other clinical trials during the study period，or participated other clinical trials （including vaccine or drug）and received medication or vaccine within 3 months before enrollment ,\n3. History of positive HPV testing (including types not covered by the trial vaccine) among the participants aged 18-45 years old;\n4. History of CIN2\u002FAIS\u002FCervical Cancer\u002FPelvic radiation therapy in female participants;\n5. History of HPV-related external genital diseases (such as genital warts, Vulvar intraepithelial neoplasia, Vaginal intraepithelial neoplasia, Penis\u002Fperianal\u002Fperineum intraepithelial neoplasia, Penile\u002Fperianal\u002Fperineal cancer) 、anal intraepithelial neoplasia and related cancer, or head and neck cancer；history of sexually transmitted diseases (including syphilis， Gonorrhea, genital chlamydia infection, genital herpes, soft chancre, sexually transmitted lymphogranuloma, inguinal granuloma, etc.);\n6. Has been diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection\u002FAIDS, SCID; Or Autoimmune Diseases (such as systemic lupus erythematosu, Rheumatoid arthritis, juvenile Rheumatoid arthritis, Pernicious Anemia, Ulcerative colitis, Type 1 diabetes, Graves' disease, hashimoto thyroiditi, etc.);\n7. History of convulsions, epilepsy, except of febrile convulsions in children 5 years of age and younger;\n8. History of severe allergy that requires medical intervention, including but not limited to severe adverse reactions caused by vaccine or drug, eg anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia sexual purpura, local allergic necrosis (Arthus reaction), widespread urticaria, dyspnea, angioedema, etc.; History of severe side effect caused by vaccination or severe allergy to any of the components of the investigational vaccine, including histidine, sodium chloride, aluminium phosphate, Polysorbate 80 and water for injection;\n9. Severe diseases, as determined by the investigator, that affect vaccination eligibility, whether past or current, include severe cardiovascular disease, severe liver and kidney disease, malignant tumor, and serious infectious disease, such as: tuberculosis, viral hepatitis, etc.;\n10. Before the enrollment, the physical examination was untreatment or uncontrolled hypertension, (18-45 year old: systolic blood pressure ≥140mmHg and \u002F or diastolic blood pressure ≥90mmHg, 9-17 year old: systolic blood pressure ≥120mmHg and \u002F or diastolic blood pressure ≥80mmHg);\n11. Coagulation disorders: such as Congenital or acquired hemophilia, Coagulation factor deficiency, clotting disorders, thrombocytopenia, etc.;\n12. No spleen or functional spleen, and no spleen caused by any condition;\n13. Receive any Immunosuppressive therapy product within 1 month prior to the first vaccination, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination)，e.g. systemic medication for glucocorticoid (\\>20mg\u002Fday or 2mg\u002Fkg\u002Fday, continuous use ≥2 weeks), but local medication can be used (such as ointment, eye drops, inhalants) Or nasal spray);\n14. Receive any immunoglobulin or blood product within 3 months prior to the first injection, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination);\n15. 3 days before vaccination, suffering from acute illness or acute exacerbation of chronic disease; using fever reducer, Antihistamines, and Analgesics(such as: Acetaminophen, Ibuprofen, loratadine, Cetirizine, etc. )\n16. Receiving inactivated vaccine or recombinant vaccine or live-attenuated vaccine or nucleic acid vaccine or adenovirus vaccine within 14 days before vaccination;\n17. History of mental disorders or family history of mental health disorder (immediate family);\n18. Plan to move out of the city before the end of the study or leave the local area for a long time during the scheduled study visit;\n19. The investigator believes that the participant has any condition that may interfere with the assessment of the purpose of the study.",true,"ALL","9 Years","45 Years",{"count":21,"type":22},330,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.",[28,29,30,31],"HPV Infection","HPV-Related Carcinoma","HPV-Related Intraepithelial Neoplasia","Genital Wart","RECRUITING","2025-12-16",{"date":35,"type":36},"2025-12-17","ACTUAL",{"date":38,"type":36},"2025-01-15",{"date":40,"type":22},"2026-01-13",{"name":42,"class":43},"Shanghai Bovax Biotechnology Co., Ltd.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":52,"minAge":53,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":44},"100394922","phase-3-evaluate-the-efficacy-immunogenicity-and-safety-of-9-valent-hpv-recombinant-vaccine-in-chinese-healthy-females-100394922","NCT04422366","Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years","Inclusion Criteria:\n\n(If the \"\\*\" option is not met during screening, the visit can be rescheduled)\n\n* Chinese women aged 20-45 who can provide legal identification and have a sexual life history;\n* The subject fully understands the study procedures, understands the risks and benefits associated with participating in the study, and voluntarily signs the informed consent;\n* Subjects are able to read, understand and fill in application forms such as diary CARDS and contact CARDS, and participate in follow-up according to the study requirements;\n* Subjects have not been screened for cervical cancer, or have been screened for cervical cancer but the results are normal;\n* \\*0 days before the gynecological visit, no sex within 48 hours, no flushing or vaginal cleaning within 72 hours, no use of vaginal drugs or preparations;Subject agrees to refrain from sexual intercourse (including anal, vaginal, or genital\u002Fgenital contact of the same or opposite sex) for 48 hours prior to any visit that includes gynecological sample collection, and to refrain from vaginal flushing, vaginal cleansing, or use of vaginal medications or preparations for 72 hours;\n* When the subjects were enrolled, the urine pregnancy test was negative (sensitivity was 25mIU\u002Fml cox-hcg), they were not in the lactation period and had no family planning within 7 months after enrollment (1 month before whole-course inoculation).2 weeks before included in the study, effective contraceptive measures has been adopted and agreed to in the first seven months after the study (vaccinations after 1 months ago) continue to adopt effective contraceptive measures (effective contraceptive measures include: the pill, injection or embedded contraception, slow-release local birth control pills, hormone patch, the intrauterine device (IUD), sterilization, abstinence, condom (men), diaphragm, cervical cap, etc.), rhythm, withdrawal and emergency contraception is unacceptable contraception;\n* \\*body temperature \\\u003C37.3℃ (underarm body temperature)\n\nExclusion Criteria:\n\nFirst dose exclusion criteria(If the \"\\*\" option is met during screening, the visit can be rescheduled)\n\n* Have been vaccinated with commercially available HPV vaccine in the past or planned to be vaccinated with commercially available HPV vaccine during the study period;Or have participated in a clinical trial of the HPV vaccine and have received a vaccine\u002Fplacebo vaccination;\n* Previous positive history of HPV;\n* Has a history of abnormal cervical cytology, including squamous intraepithelial lesions (SIL) or not clear meaning of the atypical squamous cells (ASC - US), except the atypical squamous cells - not highly squamous intraepithelial lesion (ASC - H), atypical glandular epithelial cells, or those with cervical intraepithelial neoplasia (CIN) and carcinoma in situ or abnormal cervical biopsy results such as the history;\n* Past history of anal and genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, vulvar cancer, vaginal cancer and anal cancer, etc.);\n* Received total hysterectomy or pelvic radiotherapy;\n* Cervical insufficiency or abnormal cervical structure (judged by the results of routine gynecological examination);\n* Previous sexual history (including syphilis, gonorrhea, chancre, venereal lymphatic granuloma, granuloma inguinal) or have obvious condyloma;\n* A history of seizures, convulsions or convulsions, or a family history of mental illness;\n* Have participated in other gynecology-related clinical trials within 6 months, and have used or plan to use other investigational or unregistered products (drugs or vaccines) other than the vaccine in this study within 3 months;\n* A history of severe allergies requiring medical intervention, such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc.A history of severe adverse reactions to previous vaccinations or a history of severe allergies to any of the components of the vaccine under study (histidine, polysorbate, aluminum phosphate, sodium borate, amorphous aluminum phosphate sulfate adjuvant and water for injection) (such as swelling of the mouth and throat, dyspnea, hypotension or shock, severe urticaria, etc.);\n* Subject receives any immunoglobulin or blood product within 3 months prior to the first dose of vaccination, or plans to receive such product within the next 7 months (1 month prior to the full course of vaccination);\n* Subjects present\u002Fpresent with immune impairment or have been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;\n* Immunosuppressant therapy within 1 month before the first dose of vaccination, such as long-term use of systemic glucocorticoid therapy (≥2mg\u002Fkg\u002F day, for more than 2 weeks, such as prednisone or similar drugs;Topical administration (such as ointment, eye drops, inhalant or nasal spray) not exceeding the recommended dosage in the directions or showing any signs of systemic exposure) or planning to receive such treatment within the next 7 months (1 month before the full course of inoculation);\n* Absence of spleen or functional absence of spleen, and absence of spleen or splenectomy in any case;\n* Patients with severe liver, kidney and cardiovascular diseases, diabetes or malignant tumor with complications;\n* Patients with thrombocytopenia or any coagulation disorders that may be contraindications to intramuscular injection;\n* \\* subjects received inactivated or recombinant vaccines within 14 days prior to study enrollment, or attenuated live vaccines within 28 days prior to study enrollment;\n* \\* an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);\n* \\* the first dose of vaccine was in pregnancy at the time of vaccination, or the end of pregnancy had not exceeded 6 weeks;\n* \\* after questioning, subjects had fever symptoms (subaxillary body temperature ≥37.3℃) before the first day of vaccination (within 24 hours before vaccination);\n* \\* the subject is in the menstrual period;\n* \\* severe acute vaginitis and suppurative cervicitis found by naked eye during gynecological examination (purulent secretion visible by naked eye);\n* Blood pressure on physical examination before the first dose of vaccination was higher than normal or increased (systolic blood pressure ≥140mmHg and\u002For diastolic blood pressure ≥90mmHg);\n* Gynecological examination before the first dose of vaccination suspected genital warts, or on the basis of clinical symptoms and signs suspected vulva, vagina or cervical precancerous lesions and the possibility of cancer;\n* Subjects may be unable to comply with the study procedure, comply with the agreement, or plan to permanently relocate from the region prior to completion of the study, or may be permanently absent from the region during the scheduled visit;\n* In the opinion of the investigators, the subjects had any other factors that made them unsuitable to participate in the clinical trial, so that continued participation in the study could not guarantee the maximum benefit of the subjects.\n\nSecond and third doses of vaccine were excluded criteria\n\n* new discoveries or new occurrences that meet the first dose exclusion criteria (except for articles 2, 3, 4, 21);\n* other serious adverse events: the investigator decides whether to terminate the experimental vaccination according to its treatment needs;\n* the investigator assays for any other reasons that may be considered necessary to terminate the trial vaccination.\n\nSecond and third doses of vaccine were delayed criteria\n\nVaccination may be postponed if:\n\n* fever (underarm body temperature ≥37.3℃);\n* before inoculation (on the day of inoculation), the urine pregnancy test was positive (sensitivity was 25mIU\u002Fml n-hcg);\n* acute illness or acute attack of a chronic disease or use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days before vaccination;\n* insufficient interval between other vaccines (inactivated or recombinant vaccines received within 14 days prior to vaccination, or any live attenuated vaccine received within 28 days);\n* any immunoglobulin or blood products received during vaccination should be administered at least 3 months after the vaccination;\n* other circumstances that can be postponed as judged by the researcher.","FEMALE","20 Years",{"count":55,"type":22},8000,[57],"PHASE3","This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .",[60,61,62,63,64,65,66,67,68,31,69,70,71,72],"Cervical Cancer","Vulvar Cancer","Vaginal Cancer","CIN1","CIN2","CIN3","VaIN1","VaIN2","VaIN3","VIN 1","VIN 2","VIN 3","AIS","2024-06-06",{"date":75,"type":36},"2024-06-07",{"date":77,"type":36},"2020-04-28",{"date":79,"type":22},"2029-09-15",{"name":42,"class":43},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":52,"minAge":18,"maxAge":19,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100467790","immune-persistence-after-the-whole-vaccination-shcedule-with-recombination-quadrivalent-hpv-vaccine-100467790","NCT05371353","Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine","Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n* Subjects who participated in the phase III clinical trial of non inferior efficacy of HPV tetravalent vaccine of Yangchun Center for Disease Control and Prevention (protocol No.: 4-HPV-3001), completed three doses of HPV quadrivalent vaccine and provided blood sample at months 7; Or subjects who have participated in the bridging study of HPV quadrivalent vaccine of Mianyang Center for Disease Control and Prevention (scheme No.: 4-HPV-3002), completed the whole vaccine schedule at month 0，2，6, and provided blood sample at months 7;\n* The subjects aged 9 to 17 years old at Mianyang site and their legal guardian should provide legal indentification; the subjects aged over 18 years old should provide legal indentification;\n* The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n* Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements.\n\nExclusion Criteria:\n\n* Enrolling or plan to enroll in other clinical trials (drugs or vaccines) (except that the observational clinical study and the subjects at Mianyang site are still in the post exemption safety follow-up stage of the 4-HPV-3002 trial);\n* Suffering from thrombocytopenia or any coagulation dysfunction that can be a contraindication to blood collection (such as coagulation factor deficiency, coagulation diseases, platelet abnormalities, etc.);\n* According to the investigator's judgment, the subject has any condition may interfere with process of evaluation of immune persistence.",{"count":89,"type":22},600,"OBSERVATIONAL","To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.",[93,94,62,31,63,64,65],"HPV Infections","Cervical Cancer Stage IIa",[96,97,60],"Human papillomavirus","vaccine","2024-04-15",{"date":100,"type":36},"2024-04-17",{"date":102,"type":36},"2022-05-14",{"date":104,"type":22},"2027-05",{"name":42,"class":43},2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":16,"sex":52,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100441393","phase-3-immunogenicity-and-safety-of-quadrivalent-hpv-vaccine-in-healthy-chinese-female-subjects-aged-9-to-19-years-100441393","NCT05027776","Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n1. Healthy Chinese females aged 9 to 26 years; Provide legal identification;\n2. The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n3. Had a negative urine pregnancy test on the day of enrollment, among the subjects of childbearing age; Not in the duration of breast-feeding and no birth plan within 7 months; According to the investigator's judgment that there is no possibility of pregnancy at that time: subjects have taken effective contraception, or asexual life after the last menstrual period, or use IUD, or had undergone ligation; subjects agree to continue take effective contraception such as taking OCS and condom use;\n4. No fever symptoms on the day of enrollment (aged\\> 14 years old, axillary temperature\\\u003C37.3°C; aged ≤ 14 years old, axillary temperature\\\u003C37.5°C );\n5. Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements;\n\nExclusion Criteria:\n\n1. Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials;\n2. Enrolling or plan to enroll in other clinical trials (drug or vaccine);\n3. History of positive test to HPV, history of cervical cancer (e.g. abnormal screening test results, abnormal cervical biopsy results, including CIN, LSIL, and cervical cancer) or history of pelvic radiotherapyherpes;\n4. History of diseases related to HPV infection (e.g. genital warts, VIN, VaIN, and related cancers) or history of STDs, including syphilis, gonorrhea, genital herpes, Mycoplasma genitalium, Lymphgranuloma Venereum, granuloma inguinale, etc.;\n5. Known allergy to any vaccine components or history of severe allergic diseases requiring treatment, including shock, laryngeal edema, urticarial, Henoch-Schonlein purpura, Arthus reaction, etc.;\n6. Had primary or acquired immunodeficiency such as HIV, SLE, JRA, etc;\n7. History of epilepsy and convulsions (except fever convulsions in children under 5 years of age);\n8. Subjects with existing infectious diseases such as TB, viral hepatitis, and\u002For HIV infection; or existing liver or kidney conditions, CVDs, and malignancy;\n9. Untreated\u002Funcontrolled hypertension before vaccination (aged 9 to 17 years: systolic BP≥120mmHg and\u002For diastolic BP≥80mmHg; aged more than 18 years: Systolic BP≥140mmHg and\u002For diastolic BP ≥90mmHg);\n10. With prohibitive contraindications such as Thrombocytopenia or coagulopathy;\n11. Asplenic, functionally asplenic, or splenectomy caused by any condition;\n12. Received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive such treatment from month 0 to month 7；\n13. Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period（month 0 to month 7）;\n14. Within 3 days prior to vaccination, have an acute disease or are in the acute attack of a chronic disease or have used antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, ceti Rizine, etc.);\n15. Receipt of inactivated, RNA, and recombinant vaccines within 14 days, live vaccines within 28 days;\n16. Subjects with existing mental illness, History of mental illness, or Family History;\n17. According to the investigator's judgment, the subject has any condition may interfere with process of evaluation or participating in this study cannot guarantee the object's maximum benefit.","26 Years",{"count":116,"type":22},1348,[57],"This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years",[93,94,62,31,63,64,65],[96,97,60],{"date":100,"type":36},{"date":123,"type":36},"2021-09-15",{"date":125,"type":22},"2026-09-29",{"name":42,"class":43},""]